Themes ETF Trust Themes Robotics & Automation ETF BOTT 深 滬
等待開盤 09-27 09:30:00 美东时间
38.8563
-0.513
-1.30%
華盛通- 最 高39.02
- 今 開39.02
- 成交量 6120股
- 最 低 38.32
- 昨 收 39.3691
- 總市值 77.71万
- 52周最高 45.905
- 市盈率 靜 --
- 換手率 30.60%
- 52周最低 22.0554
- 委 比 -50.38%
- 總股本 2.00万
- 歷史最高 45.905
- 量 比 0.44
- 振 幅 1.78%
- 歷史最低 22.0554
- 每 手 1
- 風險率 3.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Abbott Hosts Conference Call for Third-Quarter Earnings
ABBOTT PARK, Ill., Sept. 24, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2025 financial results on Wednesday, Oct. 15, before the market opens. The announcement ...
09-24 21:00
Abbott Declares 407th Consecutive Quarterly Dividend
ABBOTT PARK, Ill., Sept. 19, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share. This marks the 407th consecut...
09-19 21:00
Abbott Receives CE Mark For Expanded Navitor TAVI Indication; Now Approved In Europe For Severe Aortic Stenosis Across All Surgical Risk Categories
Navitor is now approved as a minimally invasive alternative to surgery for patients in Europe with symptomatic, severe aortic stenosis (a common and life-threatening heart valve disease) who are at low or intermediate
08-29 20:05
Abbott Laboratories Narrows FY2025 Adj EPS Guidance from $5.05-$5.25 to $5.10-$5.20 vs $5.16 Est
ABBOTT'S FINANCIAL GUIDANCEAbbott projects full-year 2025 organic sales growth, excluding COVID-19 testing related sales, to be 7.5% to 8.0%, or 6.0% to 7.0% when including COVID-19 testing-related sales.Abbott projects
07-17 19:32
FDA Approves Abbott's Tendyne Transcatheter Mitral Valve Replacement System To Treat People With Mitral Valve Disease
The Tendyne system replaces mitral valves that are not functioning properly due to a buildup of calcium in the base of the valves, known as severe mitral annular calcification (MAC)Tendyne offers a new treatment
05-27 21:03
Abbott Reaffirms 2025 Adjusted EPS Of $5.05-$5.25 And Consensus Of $5.15, With Organic Sales Growth Of 7.5%-8.5% And Adjusted Operating Margin Of 23.5%-24.0%
ABBOTT'S FINANCIAL GUIDANCEAbbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5%.Abbott projects full-year 2025 adjusted operating margin to be 23.5% to 24.0% of sales.Abbott projects
04-16 19:33
Abbott Increases Quarterly Dividend From $0.55 To $0.59 Per Share
Dividend increased by 7.3%Quarterly dividend payout has increased more than 60% since 2020404th consecutive quarterly dividend to be paid by Abbott since 1924ABBOTT PARK, Ill., Dec. 13, 2024 /PRNewswire/ -- Abbott
2024-12-14 00:02
AI与加密相结合的黄金时代有哪三大值得关注的趋势？
作者：William M. Peaster，Bankless；编译：邓通，金色财经 在加密领域，对人工智能代理的兴奋正在达到历史新高。 我们以前也有过个人崇拜...
2024-10-23 10:40
Gaucho Holdings' Algodon Fine Wines Unveils Newest Vintages in The U.S., Showcasing the Best of Argentina Wines
Featuring celebrated Malbecs and exclusive microvinified blends, Algodon Fine W...
2024-10-15 20:30
